CDK4/6 blockade provides an alternative approach for treatment of mismatch-repair deficient tumors

Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?

(2022) Emily J. Lelliott et al.   npj Precision Oncology

Defining the current role of immune checkpoint inhibitors in the treatment of mismatch repair-deficient/microsatellite stability-high colorectal cancer and shedding light on future approaches

(2021) Elaine Tan et al.   Expert Review of Gastroenterology & Hepatology

Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors

(2021) Inken Salewski et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition

(2021) Mana Taki et al.   CLINICAL CANCER RESEARCH

Role of TCF‐1 in differentiation, exhaustion, and memory of CD8 + T cells: A review

(2021) Jiaxue Zhang et al.   FASEB JOURNAL

Inhibition of CDK4/6 promotes CD8 T-cell memory formation

(2021) Max Heckler et al.   Cancer Discovery

Pre-existing effector T-cell levels and augmented myeloid cell composition denote response to CDK4/6 inhibitor palbociclib and pembrolizumab in hormone receptor-positive metastatic breast cancer

(2021) Colt Egelston et al.   Journal for ImmunoTherapy of Cancer

Combined Gemcitabine and Immune-Checkpoint Inhibition Conquers Anti-PD-L1 Resistance in Low-Immunogenic Mismatch Repair-Deficient Tumors

(2021) Inken Salewski et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

TCF‐1 maintains CD8 + T cell stemness in tumor microenvironment

(2021) Shuqiong Wen et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Vimentin Is at the Heart of Epithelial Mesenchymal Transition (EMT) Mediated Metastasis

(2021) Saima Usman et al.   Cancers

Targeting Extracellular Vesicles to the Arthritic Joint Using a Damaged Cartilage-Specific Antibody

(2020) Louise M. Topping et al.   Frontiers in Immunology

Abemaciclib induces atypical cell death in cancer cells characterized by formation of cytoplasmic vacuoles derived from lysosomes

(2020) Hirotsugu Hino et al.   CANCER SCIENCE

Relationship between MLH1, PMS2, MSH2, and MSH6 gene specific alterations and tumor mutational burden (TMB) in 1,057 microsatellite instability‐high solid tumors

(2020) Mohamed E. Salem et al.   INTERNATIONAL JOURNAL OF CANCER

A Phase II Study of Avelumab Monotherapy in Patients with Mismatch Repair-Deficient/Microsatellite Instability-High or POLE-Mutated Metastatic or Unresectable Colorectal Cancer

(2020) Jwa Hoon Kim et al.   Cancer Research and Treatment

Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib

(2020) Stefanie L. Groenland et al.   CLINICAL PHARMACOKINETICS

CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer

(2020) Jin Huang et al.   GUT

The immunologic tumor microenvironment in endometrioid endometrial cancer in the morphomolecular context: mutual correlations and prognostic impact depending on molecular alterations

(2020) Barbara Willvonseder et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Safety and Clinical Activity of a New Anti-PD-L1 Antibody as Monotherapy or Combined with Targeted Therapy in Advanced Solid Tumors: The PACT Phase Ia/Ib Trial

(2020) Amita Patnaik et al.   CLINICAL CANCER RESEARCH

Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial

(2020) Julien Taïeb et al.   DIGESTIVE AND LIVER DISEASE

Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms

(2019) Ibrahim Halil Sahin et al.   BRITISH JOURNAL OF CANCER

Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR+/HER2− Breast Cancer

(2019) Sara A. Hurvitz et al.   CLINICAL CANCER RESEARCH

Unraveling the Heterogeneous Mutational Signature of Spontaneously Developing Tumors in MLH1−/− Mice

(2019) Gladbach et al.   Cancers

mPGES-1 and ALOX5/-15 in tumor-associated macrophages

(2018) Andreas Weigert et al.   CANCER AND METASTASIS REVIEWS

CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought

(2018) Mary E. Klein et al.   CANCER CELL

Abemaciclib, a Selective CDK4/6 Inhibitor, Enhances the Radiosensitivity of Non–Small Cell Lung CancerIn VitroandIn Vivo

(2018) Sarwat Naz et al.   CLINICAL CANCER RESEARCH

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

(2018) David A. Schaer et al.   Cell Reports

Early Growth Response Gene-2 Is Essential for M1 and M2 Macrophage Activation and Plasticity by Modulation of the Transcription Factor CEBPβ

(2018) Tatyana Veremeyko et al.   Frontiers in Immunology

MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer

(2017) Matthew P. Goetz et al.   JOURNAL OF CLINICAL ONCOLOGY

Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling

(2017) Emily M. Cousins et al.   MOLECULAR CANCER RESEARCH

Frameshift mutational target gene analysis identifies similarities and differences in constitutional mismatch repair-deficiency and Lynch syndrome

(2017) Claudia Maletzki et al.   MOLECULAR CARCINOGENESIS

CDK4/6 inhibition triggers anti-tumour immunity

(2017) Shom Goel et al.   NATURE

First FDA Approval Agnostic of Cancer Site — When a Biomarker Defines the Indication

(2017) Steven Lemery et al.   NEW ENGLAND JOURNAL OF MEDICINE

Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature

(2017) Erik S. Knudsen et al.   Oncotarget

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

(2017) Raquel Torres-Guzmán et al.   Oncotarget

Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-Cell Responses to Autologous Dendritic/Tumor Vaccines

(2016) Jingwei Liu et al.   JOURNAL OF IMMUNOTHERAPY

The mutational profile and infiltration pattern of murine MLH1-/- tumors: concurrences, disparities and cell line establishment for functional analysis

(2016) Claudia Maletzki et al.   Oncotarget

Mesalazine and thymoquinone attenuate intestinal tumour development in Msh2loxP/loxPVillin-Cre mice

(2014) Benedikt Kortüm et al.   GUT

Regulation of T Cell Differentiation and Alloimmunity by the Cyclin-Dependent Kinase Inhibitor p18ink4c

(2014) Emily A. Rowell et al.   PLoS One

IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses

(2011) Thomas Krausgruber et al.   NATURE IMMUNOLOGY

The granulocyte-macrophage colony-stimulating factor receptor: linking its structure to cell signaling and its role in disease

(2009) T. R. Hercus et al.   BLOOD

An Msh2 Conditional Knockout Mouse for Studying Intestinal Cancer and Testing Anticancer Agents

(2009) Melanie H. Kucherlapati et al.   GASTROENTEROLOGY

Immune Response Against Frameshift-Induced Neopeptides in HNPCC Patients and Healthy HNPCC Mutation Carriers

(2008) Yvette Schwitalle et al.   GASTROENTEROLOGY